Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,113 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,113 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $46,824.08. Following the completion of the transaction, the chief accounting officer directly owned 22,874 shares in the company, valued at $506,887.84. The trade was a 8.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Alexander Azoy also recently made the following trade(s):

• On Thursday, December 18th, Alexander Azoy sold 4,343 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.25, for a total transaction of $96,631.75.
• On Tuesday, December 16th, Alexander Azoy sold 2,376 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total value of $51,986.88.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The shares were sold at an average price of $26.00, for a total transaction of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The stock was sold at an average price of $13.00, for a total value of $36,803.00.

Arcus Biosciences Stock Down 1.2%

Shares of RCUS opened at $22.02 on Friday. The company has a market cap of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $26.40. The business has a fifty day moving average of $20.96 and a 200 day moving average of $14.04. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business’s revenue was down 45.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.00) earnings per share. On average, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a report on Monday. Bank of America raised their price objective on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. Truist Financial set a $30.00 price target on shares of Arcus Biosciences in a research report on Friday, December 12th. Finally, Citigroup restated a “buy” rating on shares of Arcus Biosciences in a report on Friday, December 12th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $28.89.

Hedge Funds Weigh In On Arcus Biosciences

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after purchasing an additional 1,298,584 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Arcus Biosciences by 23.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 714,002 shares of the company’s stock valued at $5,605,000 after purchasing an additional 134,379 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in Arcus Biosciences by 10.9% during the 1st quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company’s stock valued at $159,000 after purchasing an additional 1,986 shares in the last quarter. Swiss National Bank raised its holdings in shares of Arcus Biosciences by 35.9% in the first quarter. Swiss National Bank now owns 133,596 shares of the company’s stock worth $1,049,000 after buying an additional 35,300 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Arcus Biosciences by 24.5% during the first quarter. Invesco Ltd. now owns 254,024 shares of the company’s stock worth $1,994,000 after buying an additional 50,037 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.